ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

TheraSphere With Durvalumab and Tremelimumab for HCC

ClinicalTrials.gov ID: NCT05063565

Public ClinicalTrials.gov record NCT05063565. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 4:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)

Study identification

NCT ID
NCT05063565
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boston Scientific Corporation
Industry
Enrollment
100 participants

Conditions and interventions

Interventions

  • Durvalumab (Imfinzi) immunotherapy Drug
  • TheraSphere Y-90 glass microsphere therapy Device
  • Tremelimumab immunotherapy Drug

Drug · Device

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2, 2023
Primary completion
May 31, 2027
Completion
May 31, 2027
Last update posted
Apr 28, 2026

2023 – 2027

United States locations

U.S. sites
13
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
University of Arizona- Banner Health Tucson Arizona 85724
University of California San Diego San Diego California 92093
University of California San Francisco San Francisco California 94143
Georgetown University Washington D.C. District of Columbia 20007
MedStar Washington Hospital Center Washington D.C. District of Columbia 20010
Mayo Clinic Jacksonville Florida 32224
Rush University Medical Center Chicago Illinois 60612
University of Chicago Hospital Chicago Illinois 60637
Ochsner Clinic Foundation New Orleans Louisiana 70121
University of Minnesota Minneapolis Minnesota 55455
Washington University (Barnes-Jewish Hospital) St Louis Missouri 63101
Columbia University Irving Medical Center New York New York 10032
Intermountain Health Salt Lake City Utah 84157

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05063565, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05063565 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →